S&P 500   5,263.28 (+0.28%)
DOW   39,856.47 (+0.24%)
QQQ   444.81 (+0.00%)
AAPL   171.94 (-0.79%)
MSFT   421.22 (-0.05%)
META   489.33 (-0.92%)
GOOGL   151.15 (+0.19%)
AMZN   180.57 (+0.41%)
TSLA   176.12 (-2.06%)
NVDA   905.20 (+0.30%)
NIO   4.51 (-3.43%)
AMD   180.36 (+0.43%)
BABA   72.39 (+1.12%)
T   17.65 (+0.57%)
F   13.26 (+1.53%)
MU   117.96 (-0.99%)
CGC   8.63 (-9.63%)
GE   175.78 (-2.41%)
DIS   122.38 (+1.16%)
AMC   3.66 (-15.67%)
PFE   27.86 (+0.29%)
PYPL   67.25 (+1.02%)
XOM   116.08 (+0.97%)
S&P 500   5,263.28 (+0.28%)
DOW   39,856.47 (+0.24%)
QQQ   444.81 (+0.00%)
AAPL   171.94 (-0.79%)
MSFT   421.22 (-0.05%)
META   489.33 (-0.92%)
GOOGL   151.15 (+0.19%)
AMZN   180.57 (+0.41%)
TSLA   176.12 (-2.06%)
NVDA   905.20 (+0.30%)
NIO   4.51 (-3.43%)
AMD   180.36 (+0.43%)
BABA   72.39 (+1.12%)
T   17.65 (+0.57%)
F   13.26 (+1.53%)
MU   117.96 (-0.99%)
CGC   8.63 (-9.63%)
GE   175.78 (-2.41%)
DIS   122.38 (+1.16%)
AMC   3.66 (-15.67%)
PFE   27.86 (+0.29%)
PYPL   67.25 (+1.02%)
XOM   116.08 (+0.97%)
S&P 500   5,263.28 (+0.28%)
DOW   39,856.47 (+0.24%)
QQQ   444.81 (+0.00%)
AAPL   171.94 (-0.79%)
MSFT   421.22 (-0.05%)
META   489.33 (-0.92%)
GOOGL   151.15 (+0.19%)
AMZN   180.57 (+0.41%)
TSLA   176.12 (-2.06%)
NVDA   905.20 (+0.30%)
NIO   4.51 (-3.43%)
AMD   180.36 (+0.43%)
BABA   72.39 (+1.12%)
T   17.65 (+0.57%)
F   13.26 (+1.53%)
MU   117.96 (-0.99%)
CGC   8.63 (-9.63%)
GE   175.78 (-2.41%)
DIS   122.38 (+1.16%)
AMC   3.66 (-15.67%)
PFE   27.86 (+0.29%)
PYPL   67.25 (+1.02%)
XOM   116.08 (+0.97%)
S&P 500   5,263.28 (+0.28%)
DOW   39,856.47 (+0.24%)
QQQ   444.81 (+0.00%)
AAPL   171.94 (-0.79%)
MSFT   421.22 (-0.05%)
META   489.33 (-0.92%)
GOOGL   151.15 (+0.19%)
AMZN   180.57 (+0.41%)
TSLA   176.12 (-2.06%)
NVDA   905.20 (+0.30%)
NIO   4.51 (-3.43%)
AMD   180.36 (+0.43%)
BABA   72.39 (+1.12%)
T   17.65 (+0.57%)
F   13.26 (+1.53%)
MU   117.96 (-0.99%)
CGC   8.63 (-9.63%)
GE   175.78 (-2.41%)
DIS   122.38 (+1.16%)
AMC   3.66 (-15.67%)
PFE   27.86 (+0.29%)
PYPL   67.25 (+1.02%)
XOM   116.08 (+0.97%)
NASDAQ:EMBC

Embecta (EMBC) Stock Price, News & Analysis

$13.45
+0.55 (+4.26%)
(As of 03:16 PM ET)
Today's Range
$12.85
$13.60
50-Day Range
$12.35
$17.76
52-Week Range
$12.32
$32.00
Volume
149,084 shs
Average Volume
413,141 shs
Market Capitalization
$774.45 million
P/E Ratio
14.16
Dividend Yield
4.46%
Price Target
$16.00

Embecta MarketRank™ Stock Analysis

Analyst Rating
Reduce
1.50 Rating Score
Upside/​Downside
18.4% Upside
$16.00 Price Target
Short Interest
Bearish
5.50% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
N/A
News Sentiment
0.00mentions of Embecta in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$32,500 Bought Last Quarter
Proj. Earnings Growth
3.27%
From $2.14 to $2.21 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.73 out of 5 stars

Medical Sector

451st out of 939 stocks

Surgical & Medical Instruments Industry

51st out of 98 stocks

EMBC stock logo

About Embecta Stock (NASDAQ:EMBC)

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.

EMBC Stock Price History

EMBC Stock News Headlines

EMBC Apr 2024 10.000 put
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
EMBC Apr 2024 20.000 call
Embecta (NASDAQ:EMBC) Has Affirmed Its Dividend Of $0.15
Embecta Shareholders Approve Directors and Compensation Plans
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
Embecta Shares Fall Despite Outlook Raise, Strong 1Q
Embecta Sinks As Outlook Comes In Below Consensus
Why Embecta Stock Is Tanking Today
Why Embecta Stock Is Tanking Today
Earnings Preview For Embecta
Embecta Corp's Dividend Analysis
See More Headlines
Receive EMBC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Embecta and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/09/2024
Ex-Dividend for 3/15 Dividend
2/27/2024
Dividend Payable
3/15/2024
Today
3/28/2024
Next Earnings (Estimated)
5/10/2024
Fiscal Year End
9/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:EMBC
Fax
N/A
Employees
2,200
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$16.00
High Stock Price Target
$16.00
Low Stock Price Target
$16.00
Potential Upside/Downside
+20.1%
Consensus Rating
Reduce
Rating Score (0-4)
1.50
Research Coverage
2 Analysts

Profitability

Net Income
$70.40 million
Pretax Margin
5.69%

Debt

Sales & Book Value

Annual Sales
$1.12 billion
Cash Flow
$3.99 per share
Book Value
($14.34) per share

Miscellaneous

Free Float
57,418,000
Market Cap
$766.97 million
Optionable
Optionable
Beta
0.74
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Devdatt Kurdikar (Age 56)
    President, CEO & Director
    Comp: $2.2M
  • Mr. Jacob P. Elguicze (Age 51)
    Senior VP & CFO
    Comp: $1.05M
  • Mr. Brian R. Capone (Age 49)
    VP, Chief Accounting Officer & Corporate Controller
    Comp: $645.16k
  • Mr. Jeffrey Z. Mann (Age 52)
    Senior VP, General Counsel, Head of Business Development & Corporate Secretary
    Comp: $959.45k
  • Mr. Shaun Curtis (Age 55)
    Senior Vice President of Global Manufacturing & Supply Chain
    Comp: $915.67k
  • Ms. Colleen Riley (Age 60)
    Senior VP & Chief Technology Officer
  • Mr. Pravesh Khandelwal
    VP & Head of Investor Relations
  • Ms. Ginny Blocki
    Senior Vice President of Global Marketing & Product Management
  • Ms. Jean M. Casner (Age 66)
    Senior VP & Chief Human Resources Officer
  • Mr. Tom Blount (Age 50)
    Senior VP & President of North America

EMBC Stock Analysis - Frequently Asked Questions

Should I buy or sell Embecta stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Embecta in the last year. There are currently 1 sell rating and 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "reduce" EMBC shares.
View EMBC analyst ratings
or view top-rated stocks.

What is Embecta's stock price target for 2024?

2 Wall Street analysts have issued 1-year target prices for Embecta's shares. Their EMBC share price targets range from $16.00 to $16.00. On average, they expect the company's share price to reach $16.00 in the next twelve months. This suggests a possible upside of 18.4% from the stock's current price.
View analysts price targets for EMBC
or view top-rated stocks among Wall Street analysts.

How have EMBC shares performed in 2024?

Embecta's stock was trading at $18.93 at the beginning of 2024. Since then, EMBC shares have decreased by 28.6% and is now trading at $13.51.
View the best growth stocks for 2024 here
.

When is Embecta's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our EMBC earnings forecast
.

How were Embecta's earnings last quarter?

Embecta Corp. (NASDAQ:EMBC) posted its quarterly earnings results on Friday, February, 9th. The company reported $0.61 EPS for the quarter, topping analysts' consensus estimates of $0.46 by $0.15. The company had revenue of $277.30 million for the quarter, compared to analyst estimates of $264.92 million. Embecta had a negative trailing twelve-month return on equity of 18.66% and a net margin of 4.93%. Embecta's revenue was up .6% on a year-over-year basis. During the same quarter last year, the company earned $0.93 EPS.

How often does Embecta pay dividends? What is the dividend yield for Embecta?

Embecta announced a quarterly dividend on Friday, February 9th. Investors of record on Wednesday, February 28th will be paid a dividend of $0.15 per share on Friday, March 15th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 4.44%. The ex-dividend date is Tuesday, February 27th.
Read our dividend analysis for EMBC
.

Is Embecta a good dividend stock?

Embecta (NASDAQ:EMBC) pays an annual dividend of $0.60 per share and currently has a dividend yield of 4.86%. EMBC has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 63.16%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, EMBC will have a dividend payout ratio of 27.15% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for EMBC.

What ETFs hold Embecta's stock?

ETFs with the largest weight of Embecta (NASDAQ:EMBC) stock in their portfolio include Invesco S&P Spin-Off ETF (CSD).Invesco S&P SmallCap Health Care ETF (PSCH).

What guidance has Embecta issued on next quarter's earnings?

Embecta issued an update on its FY 2024 earnings guidance on Friday, February, 9th. The company provided earnings per share (EPS) guidance of 1.950-2.150 for the period, compared to the consensus EPS estimate of 2.000. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.

Who are Embecta's major shareholders?

Embecta's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (12.20%), Vanguard Group Inc. (12.20%), River Road Asset Management LLC (5.75%), Yacktman Asset Management LP (4.64%), Charles Schwab Investment Management Inc. (2.24%) and Balyasny Asset Management L.P. (1.49%). Insiders that own company stock include David F Melcher, Devdatt Kurdikar, Jacob Elguicze and Jeffrey Z Mann.
View institutional ownership trends
.

How do I buy shares of Embecta?

Shares of EMBC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:EMBC) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners